» Articles » PMID: 11546766

Improved Lipid and Lipoprotein Profile, Hepatic Insulin Sensitivity, and Glucose Tolerance in 11beta-hydroxysteroid Dehydrogenase Type 1 Null Mice

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2001 Sep 8
PMID 11546766
Citations 115
Authors
Affiliations
Soon will be listed here.
Abstract

Excess tissue glucocorticoid action may underlie the dyslipidemia, insulin resistance, and impaired glucose tolerance of the metabolic syndrome. 11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD-1) catalyzes conversion of circulating inert 11-dehydrocorticosterone into active corticosterone, thus amplifying local intracellular glucocorticoid action, particularly in liver. The importance of 11beta-HSD-1 in glucose homeostasis is suggested by the resistance of 11beta-HSD-1(-/-) mice to hyperglycemia upon stress or obesity, due to attenuated gluconeogenic responses. The present study further investigates the metabolic consequences of 11beta-HSD-1 deficiency, focusing on the lipid and lipoprotein profile. Ad lib fed 11beta-HSD-1(-/-) mice have markedly lower plasma triglyceride levels. This appears to be driven by increased hepatic expression of enzymes of fat catabolism (carnitine palmitoyltransferase-I, acyl-CoA oxidase, and uncoupling protein-2) and their coordinating transcription factor, peroxisome proliferator-activated receptor-alpha (PPARalpha). 11beta-HSD-1(-/-) mice also have increased HDL cholesterol, with elevated liver mRNA and serum levels of apolipoprotein AI. Conversely, liver Aalpha-fibrinogen mRNA levels are decreased. Upon fasting, the normal elevation of peroxisome proliferator-activated receptor-alpha mRNA is lost in 11beta-HSD-1(-/-) mice, consistent with attenuated glucocorticoid induction. Despite this, crucial oxidative responses to fasting are maintained; carnitine palmitoyltransferase-I induction and glucose levels are similar to wild type. Refeeding shows exaggerated induction of genes encoding lipogenic enzymes and a more marked suppression of genes for fat catabolism in 11beta-HSD-1(-/-) mice, implying increased liver insulin sensitivity. Concordant with this, 24-h refed 11beta-HSD-1(-/-) mice have higher triglyceride but lower glucose levels. Further, 11beta-HSD-1(-/-) mice have improved glucose tolerance. These data suggest that 11beta-HSD-1 deficiency produces an improved lipid profile, hepatic insulin sensitization, and a potentially atheroprotective phenotype.

Citing Articles

Targeting osteoblastic 11β-HSD1 to combat high-fat diet-induced bone loss and obesity.

Zhong C, Li N, Wang S, Li D, Yang Z, Du L Nat Commun. 2024; 15(1):8588.

PMID: 39362888 PMC: 11449908. DOI: 10.1038/s41467-024-52965-4.


Deficiency of glucocorticoid receptor in bone marrow adipocytes has mild effects on bone and hematopoiesis but does not influence expansion of marrow adiposity with caloric restriction.

Schill R, Visser J, Ashby M, Li Z, Lewis K, Morales-Hernandez A Front Endocrinol (Lausanne). 2024; 15:1397081.

PMID: 38887268 PMC: 11180776. DOI: 10.3389/fendo.2024.1397081.


A genetic mouse model of lean-NAFLD unveils sexual dimorphism in the liver-heart axis.

Burelle C, Clapatiuc V, Deschenes S, Cuillerier A, De Loof M, Higgins M Commun Biol. 2024; 7(1):356.

PMID: 38519536 PMC: 10959946. DOI: 10.1038/s42003-024-06035-6.


G6PC1 and G6PC2 influence G6P flux but not HSD11B1 activity.

Hawes E, Boortz K, Oeser J, ORourke M, OBrien R J Mol Endocrinol. 2023; 71(4).

PMID: 37855366 PMC: 10616506. DOI: 10.1530/JME-23-0070.


Discovery of novel inhibitor of 11 beta-hydroxysteroid dehydrogenase type 1 using structure-based screening approach for the treatment of type 2 diabetes.

Devang N, Banjan B, V K P J Diabetes Metab Disord. 2023; 22(1):657-672.

PMID: 37255841 PMC: 10225457. DOI: 10.1007/s40200-023-01191-8.